TAZVERIK™ (tazemetostat) Approved for the Treatment of Epithelioid Sarcoma, Available from Onco360.
Onco360® has been selected by Epizyme to be the specialty pharmacy partner for TAZVERIK™ (tazemetostat), a new oral treatment for adult and pediatric patients (aged 16 years and older) with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
“The approval of TAZVERIK as a first-line therapy option for patients with unresectable metastatic or locally advanced epithelioid sarcoma is an important advancement in fighting this devastating disease,” said Paul Jardina, President and CEO, Onco360. “As a specialty pharmacy dedicated to serving people with cancer, Onco360 is honored to be selected as the exclusive specialty pharmacy partner for Tazverik. We are committed to improving the lives of patients suffering from epithelioid sarcoma.”
Epithelioid sarcoma is a rare, slow-growing subtype of soft tissue sarcoma which occurs primarily in young adults. According to the National Comprehensive Cancer Network Guidelines, approximately 13,000 patients are diagnosed with soft tissue sarcomas annually, with corresponding 5,100 deaths. Epithelioid sarcoma is believed to represent 1% of all soft tissue sarcoma diagnoses. Five-year overall survival ranges from 25-60% dependent upon tumor stage upon initial diagnosis. Greater than 90% of epithelioid sarcoma patients are found to have a genetic mutation, known as loss of INI-1 function, rendering them amenable to treatment with TAZVERIK, a novel EZH2 inhibitor.
TAZVERIK is manufactured by Epizyme, a global, commercial-stage, research-based biotechnology company, and was approved by the U.S. Food and Drug Administration (FDA) to treat adult and pediatric patients (aged 16 years and older) with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. The FDA’s approval of TAZVERIK is based on the results of an open-label, single-arm cohort of patients from the Phase II EZH-202 clinical trial (NCT02601950), which demonstrated a 15% overall rate of response. Prior to the approval of TAZVERIK, there were no medications that were specifically FDA-approved for the treatment of patients with epithelioid sarcoma.